Teva Announces Launch Of Generic Valtrex

Teva Pharmaceutical Industries Ltd. recently announced U.S. Food and Drug Administration (FDA) approval and commercial launch of its generic version of GlaxoSmithKline's antiviral product, Valtrex (valacyclovir hydrochloride) Tablets 500 mg and 1 g.

Total annual sales of the product, including brand and generic sales, were approximately $2.1B in the United States, based on IMS sales data.

About Teva
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 15 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva's sales are in North America and Western Europe.

SOURCE: Teva Pharmaceutical Industries Ltd.